Experimental p53-derived anticancer peptide · Fact sheet
PNC-27
PNC-27 is an experimental peptide studied for disrupting cancer-cell membranes. Cell-culture killing is not evidence of a safe, selective or effective human cancer treatment.
What is PNC-27?
The chimeric peptide combines a p53-related HDM-2 binding sequence with a cell-penetrating region.
Its proposed membrane effects differ from an approved systemic anticancer therapy.
Benefits & claims
Interest centers on whether membrane-associated HDM-2 can be exploited to damage cancer cells while sparing other cells.
What the evidence supports
- Cancer-cell experiments found membrane and mitochondrial disruption under laboratory conditions.
- A cervical-cell study compared cancerous and untransformed cell lines; this is not a demonstration of whole-body selectivity.
- Clinical efficacy, delivery and human safety remain unestablished.
Research areas
- HDM-2-associated cancer-cell membranes
- Cell-penetrating peptides
- Preclinical tumor biology
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for PNC-27. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- The chimeric peptide combines a p53-related HDM-2 binding sequence with a cell-penetrating region.
Formulation differences
- Its proposed membrane effects differ from an approved systemic anticancer therapy.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Human pharmacokinetics and toxicity
- Tumor response or survival benefit
- Normal-tissue selectivity in a whole organism
Side effects & risks
- A membrane-disrupting mechanism requires direct evaluation for injury to normal tissues and immune reactions.
- Cell assays cannot establish a therapeutic window, organ toxicity or interaction profile in people.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Mostly animal or lab researchThe cited studies test cancer cell lines, membrane interactions and pore formation. They do not report randomized human survival or tumor-response outcomes.
Studies
Structural and immuno-electron microscopy work in cells.
Cancer-cell mechanism experiments.
Cancerous versus untransformed cell comparison; not human treatment.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
No FDA-approved PNC-27 cancer treatment is established. The cited mechanistic studies do not document a successful human treatment program.
Preclinical evidence; no FDA-approved product
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Human pharmacokinetics and toxicity
- Tumor response or survival benefit
- Normal-tissue selectivity in a whole organism
Summary
Clinical efficacy, delivery and human safety remain unestablished.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedPNC-27 cervical cancer cell study
Cancerous versus untransformed cell comparison; not human treatment.